Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC v. Enforma

This article was originally published in The Tan Sheet

Executive Summary

Supplement firm must remove from market all Fat Trapper Plus, Exercise in a Bottle products carrying certain weight-loss claims under a stipulated preliminary injunction entered Dec. 9 by Los Angeles federal Judge Spencer Letts. Court subsequently denied Enforma's request for stay of the injunction pending appeal. Enforma was hit with a similar preliminary injunction for its Chitozyme, Acceleron weight-loss products in October (1"The Tan Sheet" Nov. 4, 2002, In Brief). Civil contempt hearing is slated for Jan. 21 barring a settlement between Enforma, FTC...

You may also be interested in...



FTC v. Enforma

Supplement firm preliminarily enjoined from making certain weight-loss claims for Chitozyme and Acceleron under Los Angeles federal Judge Spencer Letts' Oct. 30 order. FTC says Enforma must recall, repackage and relabel products while also ensuring vendors are in compliance. Enforma is seeking stay of the preliminary injunction pending appeal. FTC now is expected to seek similar injunctive relief for Enforma's Fat Trapper Plus and Exercise In A Bottle. Court's order stems from FTC's July 23 civil contempt motion (1"The Tan Sheet" Aug. 5, 2002, p. 5)...

ACC 2020: Medtronic’s Evolut TAVR Works In Low-Risk Bicuspid Study

Early results from the Low-Risk Bicuspid study of the Evolut transcatheter aortic valve replacement system showed low rates of all-cause mortality or stroke.

COVID-19 Will Spur Decentralized and Hybrid Trials – Novartis Hails Digital Investment

The reality is that many trials requiring hospital based tests and interventions cannot be replaced, but crisis will spur take up where practical.

Topics

UsernamePublicRestriction

Register

PS094936

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel